Stocks Health care BCLI

OTC · Health care

Brainstorm Cell Therapeutics Inc. (BCLI)

It posted a net loss of $10.5M. At June 30, 2026 it held $22K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.

Watch BCLI in 60 seconds

What Brainstorm Cell Therapeutics Inc. does

Brainstorm Cell Therapeutics Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on OTC under the ticker BCLI.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What Brainstorm Cell Therapeutics Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. August 14, 2026
   Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.35 versus -$0.34.
2. August 14, 2026
   Quarterly results 8-K
3. July 30, 2026
   Executive or director change 8-K
4. May 28, 2026
   Executive or director change 8-K
5. May 21, 2026
   Employee stock plan registration S-8
6. May 21, 2026
   IPO registration S-1
7. May 15, 2026
   Quarterly results 8-K
8. May 15, 2026
   Quarterly report 10-Q · period to March 31, 2026Diluted EPS -$0.19 versus -$0.45.
9. March 31, 2026
   Annual report 10-K · period to December 31, 2025Diluted EPS -$1.11 versus -$2.31.
10. March 31, 2026
    Quarterly results 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on July 28, 2026. Insider transactions on SEC

Insider trades

What the people running Brainstorm Cell Therapeutics Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider bought or sold shares on the open market in the last 90 days. The 1 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns BCLI

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

5 insiders reported holding 2,868,604 shares in total, about $2.8M at the last price.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about BCLI

What does Brainstorm Cell Therapeutics Inc. do?

Brainstorm Cell Therapeutics Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on OTC under the ticker BCLI.

Is Brainstorm Cell Therapeutics Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $10.5M.

When did Brainstorm Cell Therapeutics Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026.

Similar companies

Compare BCLI with

Compare BCLI with any company

Follow BCLI

Get an email when Brainstorm Cell Therapeutics Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow BCLI: get an email when it files

Where the numbers come from

Financial figures are the values Brainstorm Cell Therapeutics Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.